News Breaks |
|
|
| September 4, 2012 |
| 06:01 EDT |  | PFE | Pfizer receives EU marketing authorization for Inlyta
Pfizer announced that the European Commission has granted marketing authorization for INLYTA for the treatment of adult patients with advanced renal cell carcinoma, a type of kidney cancer, after failure of prior treatment with sunitinib or a cytokine. INLYTA, a kinase inhibitor, is an oral therapy that was designed to selectively inhibit vascular endothelial growth factor receptors 1, 2 and 3,1a which are proteins that can influence tumor growth, vascular angiogenesis and progression of cancer. |
|
|
News For PFE From The Last 14 Days Check below for free stories on PFE the last two weeks. |
|
|
| May 22, 2013 |
| 08:59 EDT | | PFE | On The Fly: Pre-market Movers
 Subscribe for More Information |
|
| 08:06 EDT | | PFE | Zoetis comments on Pfizer’s split-off plans for remaining interest
Subscribe for More Information |
|
| 08:04 EDT | | PFE | Pfizer announces plan to split-off remainder of Zoetis
Subscribe for More Information |
|
| 08:02 EDT | | PFE | Pfizer announces plan to split-off remainder of Zoetis
Subscribe for More Information |
|
| May 21, 2013 |
| 07:16 EDT |  | PFE | Pfizer management to meet with Leerink
Subscribe for More Information |
|
| May 20, 2013 |
| 17:04 EDT | | PFE | Pfizer discontinues phase 3 study of inotuzumab ozogamicin
Subscribe for More Information |
|
| May 16, 2013 |
| 08:55 EDT | | PFE | BofA/Merrill's pharmaceuticals analysts hold analyst/industry conference call
Subscribe for More Information |
|
|
|
|
|
